Sabby Management’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-69,103
Closed -$22K 156
2022
Q1
$22K Sell
69,103
-315,494
-82% -$337K ﹤0.01% 138
2021
Q4
$885K Buy
384,597
+18,137
+5% +$53.5K 0.13% 85
2021
Q3
$847K Sell
366,460
-33,620
-8% -$127K 0.11% 94
2021
Q2
$2.19M Sell
400,080
-78,861
-16% -$425K 0.31% 53
2021
Q1
$2.51M Buy
+478,941
New +$2.62M 0.49% 39
2015
Q1
Sell
-18,858
Closed -$108 334
2014
Q4
$108 Sell
18,858
-25,195
-57% -$197K ﹤0.01% 219
2014
Q3
$404 Buy
44,053
+28,745
+188% +$263K 0.02% 194
2014
Q2
$147K Sell
15,308
-76,000
-83% -$888K 0.01% 234
2014
Q1
$1.24M Buy
+91,308
New +$1.49M 0.07% 129

Other funds holding STAB

Sabby Management's STAB Position: Q2 2022 in Review

Sabby Management sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q2 2022, closing a stake of 69,103 shares — an estimated $22K sold.

Sabby Management first reported a position in STAB in Q1 2014 and held it in 9 quarters. The position peaked at $2.51M in Q1 2021. 35 funds tracked by Wall St. Rank hold STAB as of Q2 2022.

  • Sabby Management reported no remaining Statera Biopharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Sabby Management sold 69,103 Statera Biopharma, Inc. Common Stock shares in Q2 2022, an estimated $22K.
  • Sabby Management first reported a position in Statera Biopharma, Inc. Common Stock in Q1 2014 and held it in 9 quarters.
  • Sabby Management's Statera Biopharma, Inc. Common Stock position peaked at $2.51M in Q1 2021.
  • 35 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q2 2022.

Based on Sabby Management's 13F filing for Q2 2022, filed 15 Aug 2022.